Wearable sleep tracking vs. polysomnography: how accurate stage detection actually is, and what your sleep score really measures

Key takeaways

• Wrist wearables estimate sleep from accelerometer + photoplethysmography (heart rate / HRV) + skin temperature. They do not measure brain activity (EEG).
• Chinoy 2021 head-to-head validation across 7 devices vs polysomnography: total sleep time accurate to within 15-30 minutes; deep sleep (N3) and REM classification both 50-70 percent epoch agreement.
• Sleep scores (Whoop, Oura, Apple, Fitbit, Garmin) are vendor-defined composites with proprietary weighting; not directly comparable across brands.
• Wearables are useful for total sleep time and timing-consistency trends. They are not validated diagnostic tools for sleep apnea, insomnia disorder, or other sleep disorders.
• If sleep apnea is suspected (snoring, choking awakenings, daytime sleepiness, witnessed apneas), the appropriate next step is home sleep apnea testing or in-lab polysomnography, not wearable analysis.

What wearables actually measure

Wrist wearables estimate sleep from a small set of inputs: 3-axis accelerometer (wrist motion), photoplethysmography (PPG) for heart rate and heart-rate variability, skin temperature in newer devices, and sometimes blood-oxygen estimates from reflective pulse oximetry. They do not measure brain activity. The published clinical reference standard for sleep staging is polysomnography (PSG), which combines electroencephalography (EEG), electrooculography (EOG), submental electromyography (EMG), respiratory effort, airflow, and oxygen saturation .

The wearable's sleep stage chart is therefore a model output that estimates EEG-derived stages from non-EEG signals. The model is trained against PSG-labeled sleep, but the inputs are fundamentally indirect. Different vendors use different proprietary algorithms; even the same hardware can produce different stage breakdowns across firmware versions.

The AASM scoring standard (what the wearable is trying to estimate)

The American Academy of Sleep Medicine (AASM) scoring manual is the international reference for staging sleep into N1, N2, N3 (slow-wave / deep), and REM, in 30-second epochs. The current edition specifies the EEG, EOG, EMG, and respiratory criteria for each stage, plus arousal scoring rules. Inter-rater agreement between expert PSG technicians is roughly 80-85 percent epoch-by-epoch even with full PSG data, which sets the upper bound for any wearable that estimates the same construct .

This is important context: even gold-standard PSG scoring has irreducible noise at the epoch level. A wearable cannot reasonably be expected to do better than humans scoring full PSG; the question is how close it can get with much sparser inputs.

What validation studies actually show

Chinoy and colleagues 2021 ran the largest and best-known head-to-head wearable-vs-PSG validation in 34 healthy adults across multiple devices (Apple Watch Series 6, Fitbit Sense, Oura Ring Gen 2, Whoop 3.0, Garmin Fenix 6S, Polar Vantage V) . Headline findings:

• Total sleep time and sleep onset latency: wearables agree with PSG within roughly 15-30 minutes on average across devices.
• Wake-after-sleep-onset (WASO): biased low; wearables tend to under-detect brief awakenings (typical bias 30-60 minutes lower than PSG).
• Light vs deep (N3) sleep classification: agreement with PSG is much weaker; epoch-by-epoch accuracy commonly sits in the 50-70 percent range across published validations .
• REM detection: comparable to deep-sleep classification (roughly 50-70 percent epoch-level sensitivity in the named validations, if anything marginally harder than deep sleep) and substantially noisier than PSG.
• Performance is worse in populations with sleep disorders (insomnia, sleep apnea), atypical heart-rate patterns (atrial fibrillation), and shift workers.
• Newer devices generally outperform older ones; the Oura Ring Gen 2 and the Apple Watch with watchOS 9+ sleep-stages feature were the closer-to-PSG performers in Chinoy 2021.

De Zambotti and colleagues 2019 published an earlier comprehensive review of consumer wearable validation; the conclusions were similar: total sleep time decent, stage detection rough .

The sleep score construct (vendor-defined blackbox)

The single 'sleep score' on a wearable is a vendor-defined composite. It blends total time, stage estimates, heart rate, HRV, respiratory rate, skin temperature trend, and sometimes consistency of timing. Because the input signals are noisy and the weighting is proprietary, the same night of sleep can produce different scores across devices.

• Whoop 'Sleep Performance' weights total time and stage breakdown against an internal need calculation.
• Oura 'Sleep Score' weights total sleep time, efficiency, restfulness, REM, deep sleep, latency, and timing.
• Apple Watch reports stage estimates plus a 'sleep duration' goal; no proprietary single-score metric.
• Fitbit 'Sleep Score' (0-100) weights duration, sleep stages, and restoration heart-rate metrics.
• Garmin 'Sleep Score' (0-100) blends similar inputs with stress-balance trends.

The score correlates with subjective recovery in many users, but it is not directly comparable across brands or even firmware versions of the same brand. A 'good night' on Oura is not the same number as a 'good night' on Whoop, even when the underlying physiology is identical.

What wearables can and cannot do clinically

• Can do: track total sleep time trends, detect timing-consistency drift, surface low-HRV mornings that correlate with subjective recovery, encourage sleep-hygiene behavior change.
• Can do (newer devices, Apple Watch and Fitbit specifically): atrial fibrillation detection via PPG; FDA-cleared as a notification tool, not a diagnostic.
• Cannot do: diagnose obstructive sleep apnea (OSA). Wearable SpO2 is reflective rather than transmissive, lower signal quality than fingertip oximetry; current consumer wearables have not been validated as diagnostic for OSA.
• Cannot do: replace polysomnography for clinical sleep evaluation. Inter-night variability is high; a single wearable trace does not establish chronic patterns at clinical evidence standards.
• Cannot do: distinguish micro-arousals or sleep fragmentation at the granularity that matters for restless legs syndrome, periodic limb movements, or REM behavior disorder.

Home sleep apnea testing as the clinical alternative

If sleep apnea is the question, home sleep apnea testing (HSAT) is the appropriate next step. HSAT devices (WatchPAT, ApneaLink, etc.) record airflow, respiratory effort, oxygen saturation, and pulse rate over one or two nights at home. The result is interpreted by a sleep physician and is FDA-cleared for diagnosis of moderate-to-severe OSA in adults without significant comorbid conditions .

HSAT does not replace in-lab PSG for cases where central sleep apnea, complex nocturnal arousals, or pediatric questions are involved. But for the common adult OSA workflow, the HSAT-then-CPAP-titration pathway is well-established. Wearable data can identify users who should pursue HSAT (loud snoring, choking awakenings, daytime sleepiness, witnessed apneas, AHI suggested by SpO2 dips); the wearable data does not substitute for HSAT.

What this changes for readers

If you are using a wearable to track sleep, the most defensible interpretation is: did total sleep time go up or down, and did bedtime variability go up or down. Stage-level day-to-day comparisons are noisier than the chart suggests. Trends over weeks or months are more meaningful than single-night readings.

Persistent symptoms (loud snoring, choking awakenings, daytime sleepiness despite adequate hours, insomnia, witnessed apneas) are clinical questions that warrant evaluation regardless of what the wearable shows . The wearable data is a low-cost behavioral feedback signal, not a diagnostic.

Editorial summary

Wearable total sleep time is reasonably accurate. Stage breakdown is approximate. Sleep scores are vendor-defined composites and not cross-comparable. The validation literature is consistent across multiple devices. For sleep-disorder diagnosis, home sleep apnea testing or in-lab PSG remains the clinical pathway. Wearables are useful behavioral feedback, not a substitute for clinical evaluation.

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.